Semaglutide

Product Showcase

Information

Target Indication： Type II diabetes Obesity Strength： • Diabetes: 1.5 ml/3ml/pen, (1.34mg/ml) • Obesity: 0.68mg/ml, 1.5ml/pen; 2.27mg/3.3mg/ml,3ml/pen Formulation： • Injection  Timeline: Launch Q4.2026 in China. US ANDA Q3.2026  We have both API and finished drug product.
Chengdu Brilliant Biopharmaceutical Co.,LtdF21Chengdu Brilliant Pharmaceutical is a high-tech enterprise that engages in R&D, manufacturing and sales of therapeutic drugs. Covering API, high-end generic drugs, innovative drugs and novel drug delivery system, thus realizing comprehensive pharmaceutical industry chain layout from intermediates (INT), API and FDF, which covers small molecule(include nuclide drugs) , biological drugs and Chinese Patent Medicine.

Log in

See all the content and easy-to-use features by logging in or registering!